On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

When Bayer CEO Bill Anderson launched his Dynamic Shared Ownership (DSO) layoff plan—designed to save 2 billion euros ($2.3 ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

Supreme Group said the deal deepens its expertise in rare disease and pharma and expands the creative and omnichannel ...

“We’ll be putting initially a small tariff on pharmaceuticals but in one year—one and a half years maximum—it’s going to go ...

Raising awareness of medical products and services is a marathon, not a sprint, and Babson Diagnostics has therefore selected a star with plenty of stamina for a long-term partnership. | Raising ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

Thermo Fisher Scientific has implemented a string of layoffs in Carlsbad, California, in recent years, but it appears the ...

The company has launched the ad campaign with three patient ambassadors: Brian, Jeanette and Jennifer, each of whom is ...

BioMarin revealed topline results for the early-stage candidate, BMN 333, that suggest it is a “potentially superior version ...

In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, which include taking a ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...